Malaysian Genomics Resource Centre Berhad, (0155) Fair Value & Analysis
Healthcare · MY · Market cap 43.8M MYR
Fair value as of: Jul 12, 2026
From 10 valuation models · updated 29 days ago
Fair value updated Jul 12, 2026, revised from 0.0500 MYR to 0.0300 MYR (−40.0%) since Jun 25, 2026. Share price +8.6% over the past month.
A solid business, but screening 90% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.0500 MYR). The favourable scenario is already priced in.
- The model range is unusually wide (0.0100 MYR to 0.0500 MYR). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 0.1450 MYR – 2.72 MYR · fair‑value band 0.0100 MYR – 0.0500 MYR · the 0.3150 MYR price screens above the 0.0300 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Malaysian Genomics Resource Centre Berhad, (0155) currently trades at 0.3150 MYR, while our model-based Fair Value estimate is 0.0300 MYR, implying the stock looks roughly 90.5% overvalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Malaysian Genomics Resource Centre Berhad, generated revenue of 9.3M MYR at a net margin of -5.3%. Revenue grew 96.7% year over year. It earns a return on equity of -5.1%. Net debt stands at 6.1M MYR. Fundamentals as of Jul 12, 2026
Our scenario range runs from 0.0100 MYR (bear case) to 0.0500 MYR (bull case); at 0.3150 MYR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 103% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -90%, 0155 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: DCF Models (0.1300 MYR) versus Asset-Based (0.0700 MYR). Highest evidence: Growth DCF (80).
Notify me when 0155 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 80
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia.
Full company description
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia. The company offers genetic screening services that includes Dtect and Origene genetic testing solutions which provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits. It also provides immunotherapy and cell therapy which offers mesenchymal stem cells derived from ethically sourced human umbilical cords, as well as natural killer cell therapies designed to strengthen the body's immune response that are relevant in the treatment of cancers, autoimmune diseases, and other complex conditions. In addition, the company offers genome sequencing and bioinformatics services; personalized supplements; cellular therapy for regenerative health; and cell-free therapy for regeneration and repair. Further, it is involved in dealing in capital markets and derivative instruments; acting as general merchants; research, development, and commercialization of biopharmaceutical products and services; business relating to life sciences/cell lab and by products; and distribution of healthcare products, beauty products, and precision medicine. Additionally, the company provides system developments and information technology comprising software and hardware, as well as other human health services and general medical services. Malaysian Genomics Resource Centre Berhad was incorporated in 2004 and is headquartered in Petaling Jaya, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Malaysian Genomics Resource Centre Berhad, reported revenue of 8.0M MYR in FY2026 versus 28.4M MYR in FY2022, a compound −27.1%/yr. Reported net income was −2.4M MYR in FY2026.
0155 screens 90% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Malaysian Genomics Resource Centre Berhad, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Malaysian Genomics Resource Centre Berhad, (0155) overvalued or undervalued?
What is the fair value of 0155?
What is the quality score of 0155?
What is the revenue of Malaysian Genomics Resource Centre Berhad, (0155)?
What is the net profit margin of 0155?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Malaysian Genomics Resource Centre Berhad, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.